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Abstract
Background: The aim of this study was to evaluate the diagnostic performance of microRNA-133a in 
the diagnosis of acute myocardial infarction (AMI).
Methods: Major databases including PubMed, Embase and the Cochrane Library were searched 
for case-controlled studies comparing AMI and non-AMI patients. The outcome was evaluated by the 
relative expression of microRNA-133a in plasma or serum. The Mantel-Haenszel odds ratio (OR) was 
calculated using a fixed-effects model meta-analysis for the outcome. The primary outcomes of interest 
were pooled sensitivity, specificity and diagnostic accuracy of microRNA-133a for AMI. 
Results: Out of 137 identified related articles, 10 were found to conform with the inclusion and ex-
clusion criteria of the study. The 10 case-controlled studies contained complete data for 1,074 patients 
(with no restrictions of race, age or sex), and a database containing 137 patients from the registry of 
each study. In addition to low heterogeneity, a statistically significant increase was found in overall  
microRNA-133a expression between AMI vs. non-AMI; the pooled OR was 22.84 (95% confidence 
interval [CI] 13.87–37.63), sensitivity was 0.84 (95% CI 0.75–0.90), specificity was 0.82 (95% CI 
0.74–0.89) and area under curve (AUC) was 0.90 (95% CI 0.87–0.92). 
Conclusions: Based on the meta-analysis of ten case-controlled studies including 1,074 patients,it was 
found that the level of microRNA-133a in blood serum or plasma maybe used as a diagnostic biomarker 
of AMI. (Cardiol J 2018; 25, 2: 260–267)
Key words: diagnostic accuracy/value/performance, acute myocardial infarction,  
microRNA-133a/miR-133a, meta-analysis
Introduction
Myocardial injury resulting from acute myo-
cardial infarction (AMI) can cause blood circulation 
disorder and chest discomfort similar to heartburn 
symptoms, and can even lead to heart failure or ces-
sation of blood flow [1]. AMI is a common coronary 
artery disease, with risk factors including smoking 
and hypertension present in nearly 90% of patients 
[2]. Environmental pollution, including noise and 
air pollution, can also have adverse effects on 
myocardial infarction (MI) [3]. The pathogenesis of 
AMI involves the accumulation of collagen fibers, 
resulting in myocardial fibrosis. Usually, healthy 
people have low expression levels of collagen, but 
in patients with MI the affected tissue and sur-
rounding area have an increased expression [4]. 
Although diagnostic, assessment and therapeutic 
techniques such as ultrasound, biomarkers such 
as the C3G protein and stem cell transplantation, 
respectively, have been used successfully in  detec-
tion, diagnosis and treatment of myocardial injury 
[5–7], there is still a need to further explore novel 
approaches for the diagnosis and treatment of AMI 
and to understand the pathophysiology of AMI.
MicroRNA (miRNA) is a short chain gene-
editing, noncoding single-stranded ribonucleotide 
that can bind to messenger RNA (mRNA) on its 
poly-adenylated tail end (3’-UTR) in the non-
coding region to inhibit or promote its degradation 
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[8]. One kind of miRNA can interact with a vari-
ety of mRNAs, and one mRNA may interact with 
a variety of miRNAs together forming a sophisti-
cated regulatory system. Recently, many studies 
have shown that after MI, the detection of blood 
miRNA expression can be used as a diagnostic and 
prognostic tool for AMI. For example, miRNA-21 
expression can be increased to reduce the size 
of the infarct injury [9], miRNA-1 can be used as 
a potential molecular biomarker for AMI [10], and 
miRNA-133a can be used as a long-term prognostic 
indicator for patients after MI [11].
Studies have shown that the miRNA-133a 
expression level in blood and is related to AMI 
[12], and this interplay suggests that miRNA-133a 
could be used as a diagnostic molecular biomarker 
of AMI [13, 14]. MicroRNA-133a is a member of the 
miRNA-133 family. The aim of the present study is 
to determine the diagnostic value of the miRNA-
-133a expression level for AMI using a statistical 
method of meta-analysis.
Methods
Document retrieval
Keywords were searched in PubMed, Medline 
and Embase databases using the following medi-
cal subject headings (MeSH): “microRNA-133a”, 
“miR-133a”, and “myocardial infarction” The data 
was obtained by retrieving relevant literature 
references based on information about the studies 
included.
Inclusion and exclusion criteria
Two reviewers independently screened all 
related titles and abstracts using the following 
inclusion and exclusion criteria. Inclusion criteria: 
1) patients with clinical diagnosis of AMI; 2) the 
published study was a case-control design study; 
3) the study was originally published in English 
within the past 10 years (range from 2006.11 
to 2016.11); 4) the study provides accurate and 
complete information about AMI patients; 5) the 
study was assessed as a high-quality study; 6) the 
target miRNA of samples was normalized to an 
endogenous miRNA with the calculation formula 
2–∆∆Ct: 2exp (mean Ct endogenous controls – Ct 
target miRNA). Exclusion criteria: 1) patients 
with congenital heart disease; 2) a review of the 
literature, meetings and correspondence letters; 
3) experimental design involved an animal model; 
4) specimen source from tissue, secretions or 
excretions.
Evaluation of the quality of  included studies
Two investigators systematically assessed the 
quality of each article included in the meta-analysis 
according to the Quality Assessment of Diagnos-
tic Accuracy Studies tool (QUADAS-2) with 11 
entries for the answer “yes”, “no” or “unclear”. 
The “yes” answer is given a plus one-point score, 
the “no” answer is given a minus one-point score, 
and the “unclear” answer contributed to zero-point. 
A score of 7 points or more was considered high 
quality. Discrepancies were resolved by discussion 
to reach a consensus.
Data extraction
Two reviewers independently extracted rel-
evant data required for research purposes from 
the studies included. When discrepancies were 
encountered, either they were discussed until dif-
ferences were settled or the two reviewers were 
assisted by a third staff member until a consensus 
was reached. Data extracted from the literature 
included: first author, year of publication, source 
documents, case or control group of patients who 
participated in the study, the method of detection 
of miRNA and type of specimen.
Statistical analysis
After successful extraction of data, Stata 14.0 
software was used for the meta-analysis. The pooled 
odds ratios (OR) were calculated and the associated 
95% confidential intervals (CIs) using a fixed or 
random effects model with the statistical method 
of Mantel-Haenszel (M-H) or DerSimonian-Laird 
(D-L). Thevariability issue was addressed in results 
across studies by using the I2 statistic and p-value 
obtained following the meta-analysis instructions 
of Stata. The analysis results include 1) publica-
tion bias and heterogeneity of included studies; 
2) combined effect of the size of included studies; 
3) being included in the study sensitivity, specificity, 
and diagnostic OR; and 4) subgroup analysis based 
on type of AMI: ST-segment elevation myocardial 
infarction (STEMI) and non-ST-segment elevation 
myocardial infarction (NSTEMI).
Publication bias analysis was conducted with 
a comprehensive program of statistical and graphi-
cal routines for undertaking meta-analysis of diag-
nostic performance in Stata. Primary data combina-
tion is performed within the bivariate mixed-effects 
binary regression modeling framework. The model 
specification, estimation and prediction are carried 
out following the instructions in Stata release 14.0 
(StataCorp LP, College Station, TX, USA).
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Using coefficients and variance-covariance 
matrices estimated by the optimal model, the sum-
mary operating sensitivity and specificity (with 
confidence and prediction contours in the summary 
receiver operating characteristic [ROC] curve 
space), the summary likelihood and ORs were 
also calculated. The global and relevant test per-
formance metric-specific heterogeneity statistics 
are also provided. Studies of the meta-analytical 
integration of the diagnostic accuracy facilitate the 
extensive statistical and graphical data synthesis 
and exploratory analyses of the heterogeneity, 
covariate effects, publication bias and impact. The 
Bayes’ nomograms and likelihood ratio matrices 
may be obtained and used to guide the clinical 
decision-making process.
Results
Literature search results
The initial literature search retrieval process 
is shown in Figure 1 total of 137 publications 
relevant to miRNA-133a in the English literature 
were searched, according to the inclusion and ex-
clusion criteria. In summation, 10 articles met the 
inclusion criteria [12–20]. The documents included 
are contained in the basic information as shown in 
Tables 1 and 2.
Figure 1. Flowchart of the study selection process.
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Document publication bias  
and heterogeneity test
The results of Begg’s rank correlation test 
were as follows z = –0.7, p = 0.484; Egger regres-
sion analysis t = –0.23, p = 0.824; and the effect 
of size in detecting heterogeneity was I2 = 41.7%, 
p = 0.071. The results showed that studies in-
cluded have moderate publication bias (Fig. 2A), 
and low heterogeneity (25% < I2 <50%; Fig. 2B). 
Accordingly, a fixed effect model to merge the effect 
size of the studies included was selected.
Meta-analysis and subgroup meta-analysis
The combined analysis of the included studies 
revealed that sensitivity was 0.83 (95% CI 0.78– 
–0.88), the specificity was 0.78 (95% CI 0.70–0.84), 
Figure 2. Publication bias test and heterogeneity of the included studies. A. Funnel plot of the included studies; 
B. Labbe plot for detecting heterogeneity; AMI — acute coronary syndrome; NSTEMI — non-ST-segment elevation 
myocardial infarction; OR — odds ratio.
Figure 3. Diagnostic probabilities and summary receiver operating characteristic (SROC) curve; A. Line graph of 
post-test probabilities versus prior probabilities between 0 and 1 using summary likelihood ratios; CI — confidence 
interval; NPV — negative predictive value; PPV — positive predictive value; B. Summary receiver operating charac-
teristic curve; AUC — area under curve.
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Figure 4. Forest plot comparing acute myocardial infarction (AMI) and non-AMI in relation to expression of miR-133a; 
CI — confidence interval.
Figure 5. Forest plot comparing ST-segment elevation myocardial infarction (STEMI) and non-NSTEMI in relation to 
expression of miR-133a; CI — confidence interval.
positive likelihood ratio was 3.7 (95% CI 2.7–5.1), 
the negative likelihood ratio was 0.21 (95% CI 
0.15–0.30), the diagnostic OR was 17 (95% CI 
10–30), the area under the summary ROC curve 
was 0.88 (95% CI 0.85–0.90) (Fig. 3A, B).
Additionally, a meta-regression analysis was 
performed to determine the reason for the mod-
erate heterogeneity. Results showed that  moder-
ate heterogeneity originated from the difference 
between the AMI and STEMI and the different 
methods of detecting miRNA-133a. Thus, a sub-
group meta-analysis was performed based on 
results of the meta-regression analysis. Combined 
results of AMI vs. non-AMI are shown in the 
figures as follows (Fig. 4), pooled OR was 22.84 
(95% CI 13.87–37.63), I2 = 62.2%, p = 0.021; 
STEMI vs. NSTEMI; (Fig. 5), pooled OR was 12.46 
(95% CI 5.24–29.63), I2 = 0.0%, p = 0.615. The 
pooled OR of the TaqMan detection method was 
28.29 (95% CI 12.00–66.68), I2 = 21.7%, p = 0.279; 
The pooled OR of the SYBR detection method 
was 17.01 (95% CI 10.30–28.09), I2 = 45.8%, 
p = 0.074 (Fig. 6). 
Discussion
This analysis showed that the expression 
level of miRNA-133a after AMI is increased in 
plasma and serum, and confirmed the diagnostic 
performance of miRNA-133a during the forma-
tion of AMI. This finding has important clinical 
significance for early diagnosis of AMI and its 
treatment. MicroRNAs are a class of endogenous 
short RNA fragments, that do not encode proteins, 
but are involved in many biological processes as-
sociated with signal transduction, and therefore 
they have been used to diagnose heart failure or 
hypertensive patients [21, 22]. In addition, some 
reports confirmed that miRNAs could perhaps be 
used as molecular biomarkers for diagnosis and 
prognosis of MI diagnosis and prognosis [23, 24]. 
Using a number of case-control studies, a compre-
hensive analysis was performed of the expression 
of miRNA-133a in patients with AMI and non-AMI 
in their blood, and results showed increased ex-
pression of miRNA-133a in blood of patients with 
AMI. Moreover, results of a summary ROC curve 
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analysis suggest that miRNA-133a may be used for 
diagnosis of AMI patients.
Additionally, an interesting idea was sparked 
by the subgroup analysis result: the TaqMan detec-
tion method for miRNA-133a may be more accurate 
than the SYBR Green detection method. Based on 
TaqMan had pooled OR value 28.29 vs. 17.01 of the 
SYBR Green, calculations for each group’s AUC 
was done, also an un-paired test between the two 
groups ORs was performed. The results are positive 
and statistically significant according to these find-
ings. That is to say, the TaqMan detection method 
is superior to the SYBR Green method just as the 
other authors have described in prior studies [25].
Numerous studies have investigated whether 
miRNA-133a could be an optimal biomarker for 
patients with AMI. The results showed inconsist-
ency in the diagnostic value of miRNA-133a. The 
results of several study analyses support a role 
for miRNA-133a as a biomarker [16, 19, 23, 24, 
26]. However, the number of AMI patients and 
healthy controls participating in these studies 
were relatively small. Widera et al. [27] reported 
that there was a large overlap between patients 
with unstable angina or MI in relation to the level 
of miRNA-133a. Kuwabara et al. [12] reported 
significantly increased serum levels of miRNA-
-133a in patients with AMI, as well as in patients 
with unstable angina pectoris. These studies had 
a larger sample size than the studies mentioned 
above and support a role for miRNA-133a as 
a diagnostic biomarker. Additionally, the present 
data adequately supports the suggestion that 
miRNA-133a could be used as a biomarker for 
AMI diagnosis, particularly considering that the 
pooled AUC of the ROC curve is 0.88 (95% CI 
0.85–0.90) (Fig. 3B). Overall, the results of this 
meta-analysis indicate that miRNA-133a can be 
used as a diagnostic biomarker for AMI.
Recently, many studies have shown that miRNA 
circulating in the blood may affect mortality in 
patients with AMI [11, 27], and miRNA concentra-
tion may influence the prognosis of patient 1-year 
survival [28, 29]. In addition, a few studies have 
shown that miRNAs are involved in myocardial 
remodeling [30, 31]. Although, according to the re-
sults of these reports, the molecular mechanism of 
miRNA involvement in AMI remains largely unclear, 
the miRNA may still be used as molecular diagnosis 
biomarker of AMI. Moreover, the results of the hi-
erarchical summary ROC curve analysis were also 
consistent with other results of this meta-analysis.
Limitations of the study
This study has its own limitations. First,  analysis 
is based on a relatively small study population. Ad-
ditionally, there are individual and regional differences 
between research groups. Moreover, a larger group of 
patients should be included in this study to support 
more reliable results. In addition, the studies included 
miRNA expression levels were measured only at one 
point in time, with no continuous detection. which 
reduces the reliability of this study.
Conclusions
In short, the present study confirmed the 
diagnostic role of miRNA-133a in AMI patients. 
Figure 6. Forest plot of different detection methods of the expression of miR-133a; CI — confidence interval.
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However, compared with the present gold standard 
biomarkers such as creatine troponin T, troponin I 
and MB isoenzyme of creatine kinase, miRNA 
is not the best candidate at the present time due 
to protocol and cost of these detection methods. 
So, before miRNA-133a becomes commonly used 
for AMI patients clinically. Further investigation 
should be conducted to obtain accurate statistical 
analyses, and results should be subjected to further 
inquiry and analysis.
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